Results 1 to 10 of about 14,994 (162)

Low-dose primaquine for falciparum malaria [PDF]

The Lancet Infectious Diseases, 2014
Item does not contain ...
Bousema, Teun, Drakeley, Chris, Eziefula, Alice C, Pett, Helmi   +3 more
core   +5 more sources

Primaquine Therapy for Malaria [PDF]

Clinical Infectious Diseases, 2004
Primaquine is the only available drug for preventing relapse of malaria, and confusion surrounds its use. This review examines the wide range of clinical applications of primaquine described in the medical literature between 1946 and 2004. The risk of relapse of Plasmodium vivax malaria without primaquine therapy ranged from 5% to 80% or more ...
Baird, J. Kevin, Hoffman, Stephen L.
openaire   +3 more sources

The reality of using primaquine [PDF]

Malaria Journal, 2010
La primaquine est actuellement le seul médicament utilisé pour la guérison radicale de l'infection à Plasmodium vivax. Malheureusement, son utilisation n'est pas sans risque. Les patients présentant un déficit en glucose-6-phosphate déshydrogénase (G6PD) sont plus sensibles à l'hémolyse lorsqu'ils reçoivent de la primaquine.
Kathy Burgoine, Germana Bancone, François Nosten   +2 more
openaire   +4 more sources

Primaquine: the risks and the benefits [PDF]

Malaria Journal, 2014
La primaquine est le seul antipaludique généralement disponible qui prévient les rechutes dans le paludisme à vivax et à ovales, et le seul gamétocytocide puissant dans le paludisme à falciparum. La primaquine devient de plus en plus importante à mesure que les pays d'endémie palustre se dirigent vers l'élimination, et bien qu'elle soit largement ...
Elizabeth A. Ashley, Elizabeth A. Ashley, Judith Recht, Nicholas J. White, Nicholas J. White   +4 more
openaire   +3 more sources

Adequate Primaquine for Vivax Malaria [PDF]

Journal of Travel Medicine, 2006
Treatment of vivax malaria with primaquine prevents the relapse of infection from residual liver stages of the parasite. Inadequate dosage is related to a higher relapse risk.A comparison was made of vivax malaria relapse-prevention treatments with primaquine 22.5 mg or 30 mg daily for 14 days on 146 reports to the Australian Army Central Malaria ...
Kitchener, S., Nasveld, P., Bennett, S., Torresi, J.   +3 more
openaire   +4 more sources

Lead clinical and pre-clinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations [PDF]

, 2014
To achieve malarial elimination we must employ interventions that reduce the exposure of human populations to infectious mosquitoes. To this end, numerous anti-malarial drugs are under assessment in a variety of transmission-blocking assays which fail to
Blagborough, A.M., Brock, P.M., Churcher, T.S., Delves, M.J., Gething, P.W., Ghani, A.C., Leroy, D., Sala, K.A., Sinden, R.E., Upton, L.M.   +9 more
core   +4 more sources

Are transnational tobacco companies' market access strategies linked to economic development models? A case study of South Korea. [PDF]

, 2013
Transnational tobacco companies (TTCs) have used varied strategies to access previously closed markets. Using TTCs' efforts to enter the South Korean market from the late 1980s as a case study, this article asks whether there are common patterns in these
Amon, A, Asgari, M, Blake, C, Choi, A, Erben, T, Glazebrook, K, Harnois-Déraps, J, Heymans, C, Hildebrandt, H, Hoekstra, H, Johnson, A, Joudaki, S, Klaes, D, Kuijken, K, Lidman, C, Mead, A, Miller, L, Parkinson, D, Poole, GB, Schneider, P, Viola, M, Wolf, C   +21 more
core   +6 more sources

Population Pharmacokinetics of Primaquine in the Korean Population [PDF]

Pharmaceutics, 2021
While primaquine has long been used for malaria treatment, treatment failure is common. This study aims to develop a population pharmacokinetic model of primaquine and its metabolite, carboxyprimaquine, and examine factors influencing pharmacokinetic variability.
Woo-Yul Lee, Dong-Woo Chae, Choon-Ok Kim, Sang-Eun Lee, Yee-Gyung Kwak, Joon-Sup Yeom, Kyung-Soo Park   +6 more
openaire   +4 more sources

A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan. [PDF]

, 2008
BACKGROUND: Vivax malaria remains a major cause of morbidity in the subtropics. To undermine the stability of the disease, drugs are required that prevent relapse and provide reservoir reduction. A 14-day course of primaquine (PQ) is effective but cannot
Erasmus, Panna, Kolaczinski, Jan, Leslie, Toby, Mayan, Ismail, Mohammed, Nasir, Rowland, Mark, Whitty, Christopher JM   +6 more
core   +3 more sources

Pharmacokinetics and Pharmacodynamics of (+)-Primaquine and (−)-Primaquine Enantiomers in Rhesus Macaques (Macaca mulatta) [PDF]

Antimicrobial Agents and Chemotherapy, 2014
ABSTRACT Primaquine (PQ) remains the sole available drug to prevent relapse of Plasmodium vivax malaria more than 60 years after licensure. While this drug was administered as a racemic mixture, prior studies suggested a pharmacodynamic advantage based on differential antirelapse activity and/or toxicities
Larry A. Walker, Phisit Khemawoot, Rawiwan Imerbsin, Aruna Sampath, Charlotte A. Lanteri, Paktiya Teja-Isavadharm, Pattaraporn Vanachayangkul, Colin Ohrt, N. P. Dhammika Nanayakkara, David Saunders, Babu L. Tekwani, Montip Gettyacamin, Raveewan Siripokasupkul   +12 more
openaire   +3 more sources